Product Description
PF-07264660 is a drug candidate being developed as both an intravenous and subcutaneous injection by Pfizer. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05496738?term=PF-07264660&draw=2&rank=1)
Mechanisms of Action: IL4 Inhibitor, IL13 Inhibitor, IL33 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: Eastern America
Company Founding Year: 1849
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Canada, China, Germany, Japan, Poland, United States
Active Clinical Trial Count: 5
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Dermatitis, Atopic
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05995964 |
C4531002 | P2 |
Recruiting |
Dermatitis, Atopic |
2026-10-19 |
12% |
2026-02-14 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
CTR20250117 |
CTR20250117 | P1 |
Completed |
Dermatitis, Atopic |
2025-09-04 |
2025-09-28 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT06712082 |
C4521003 | P1 |
Completed |
Healthy Volunteers |
2025-09-04 |
50% |
2025-09-26 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
NCT05496738 |
C4521001 | P1 |
Completed |
Healthy Volunteers |
2024-05-06 |
50% |
2024-06-07 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
CTR20242718 |
CTR20242718 | P2 |
Recruiting |
Dermatitis, Atopic |
None |
2025-06-29 |
Patient Enrollment|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/09/2026 |
News Article |
Pfizer's Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis |